Today: 19 May 2026
Browse Category

NYSE:BMY 10 October 2025 - 21 December 2025

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bank of America upgraded Bristol-Myers Squibb to “Buy” on Dec. 16, raising its price target to $61. BMY shares traded at $53.66, down 1.15% as of 2:00 p.m. Institutional interest increased, with Shorepoint Capital Partners opening a new position. Analysts cited strong Q3 results and a pipeline of 2026 catalysts as factors in the valuation debate.
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 on December 16 after Bank of America upgraded the stock to Buy and raised its price target to $61, citing confidence in the company’s R&D pipeline. The board also increased the quarterly dividend to $0.63 per share, payable February 2, 2026, marking a 1.6% annual increase and the 17th consecutive yearly hike.
16 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb shares rose 3.6% to $54.29 Monday after Bank of America upgraded the stock to Buy and raised its price target to $61. The stock added another 0.6% in after-hours trading. Volume in extended trading reached about 1.25 million shares. Analysts cited the company’s R&D pipeline and upcoming catalysts as key drivers.
16 December 2025
··
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb shares rose 2.5% to $52.50 by mid-day Friday after Guggenheim upgraded the stock to Buy with a $62 target. The company announced a 1.6% dividend increase to $0.63 per share, its 17th consecutive annual raise. The FDA granted Priority Review for Opdivo in Hodgkin lymphoma, and approved Breyanzi for marginal zone lymphoma earlier this month.
12 December 2025
·
Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb shares closed at $52.15 on December 5, 2025, after a week marked by a surprise Alzheimer’s drug trial update, major hematology data, and a legal setback. The stock rebounded 7% over several days, adding $7 billion in market value. BMY trades at a trailing P/E of 17.5x with a 4.7–5% dividend yield. Analyst consensus rates the stock a hold, with modest upside expected.
7 December 2025
·
Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb shares rallied this week, trading near $50.55 after news on its Alzheimer’s drug Cobenfy, an AI drug discovery milestone, and a key lawsuit ruling. The company declared a $0.62 quarterly dividend, bringing the annual yield to about 4.9%. Market cap stands at $104 billion. Despite the rebound, BMY shares remain down roughly 15% for 2025.
4 December 2025
··
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb shares jumped over 6% to $51.32 intraday on December 3, 2025, after the company announced a data review and patient re-enrollment for its ADEPT-2 Alzheimer’s psychosis trial. The stock rally follows strong Q3 results and analyst upgrades, despite ongoing legal risks and looming patent expiries.
3 December 2025
····
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

A U.S. judge on Dec. 1, 2025, revived a $6.7 billion lawsuit against Bristol-Myers Squibb over Celgene contingent value rights, sending BMY shares down 1.89% to $48.25. The stock marked its third straight loss, underperforming peers as legal risks weighed despite positive hematology data at ASH 2025. Market cap stood at about $98 billion. Trading volume was below average at 14.5 million shares.
3 December 2025
··
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

A U.S. federal judge allowed a $6.7 billion lawsuit against Bristol-Myers Squibb over its 2019 Celgene acquisition to proceed, rejecting the company’s motion to dismiss key claims. BMY shares closed at $49.18 on December 1, up 7–8% over five days, but remain down for the year. The company’s annual dividend yield is about 5%. New cell therapy approvals and strong ASH 2025 hematology data also drew investor attention.
2 December 2025
·
Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb (BMY) Stock on November 29, 2025: 5.4% Dividend, Heavy Institutional Buying and a ‘Hold’ Consensus

Bristol-Myers Squibb closed November 28 at $49.20, down 22% from its March high and trailing the S&P 500 by over 30 percentage points year-to-date. The stock’s 5.4% dividend yield drew headlines November 29, as analysts maintained “Hold” ratings and institutional investors quietly increased stakes. Valuation metrics show BMY trading at steep discounts to pharma peers.
30 November 2025
··
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Bristol Myers Squibb shares rose 4.3% to $48.24 Monday after renewed investor interest in Factor XIa blood-thinner drugs and its candidate milvexian. The company announced a hematology-focused virtual investor event for December 11. Despite the gain, BMY remains down about 14% for the year, trailing the S&P 500’s 13.6% rise. Q3 earnings beat expectations, with revenue up 3% to $12.2 billion.
24 November 2025
·
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson have halted the Phase 3 Librexia ACS trial of milvexian in acute coronary syndrome after an interim review showed the drug was unlikely to meet its main efficacy goal. BMY shares fell following the announcement. No new safety issues were reported. The trial had aimed to enroll about 16,000 patients worldwide.
14 November 2025
···
5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

Walmart shares dropped up to 3% after the company named John Furner as CEO, replacing Doug McMillon effective February 2026. Merck agreed to buy Cidara Therapeutics for $9.2 billion in cash, gaining access to a late-stage flu prevention drug. U.S. equity futures fell sharply as tech stocks continued to slide and traders lowered expectations for a near-term Fed rate cut.
14 November 2025
·····
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol Myers Squibb priced €5 billion in senior notes across five tranches, with closing expected Nov. 10; proceeds will fund a debt tender offer running through Dec. 3. The company agreed to a $239 million settlement in a Celgene class action, pending court approval. BioNTech raised its 2025 revenue outlook after receiving payments from a new BMS alliance. FDA approved a generic for Sprycel on Nov. 7.
9 November 2025
··
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb reported Q3 adjusted EPS of $1.63 on $12.2 billion revenue, beating estimates, and raised its 2025 outlook. Shares rebounded 3–4% after hitting a 52-week low, with dividend yield now near 5.5%. New drugs like Opdivo and Eliquis outperformed, offsetting a sharp Revlimid decline. The company acquired Orbital Therapeutics and launched schizophrenia drug Cobenfy, posting $62 million in early sales.
30 October 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 15.10.2025

Bristol-Myers Squibb (BMY) scored 88% under Validea’s Partha Mohanram P/B Growth Investor model, the highest among 22 strategies reviewed. Most key financial tests passed, but the stock failed the research and development to assets metric.
15 October 2025
·
1 2

Stock Market Today

  • Polymarket Teams Up with Nasdaq Private Market to Settle Pre-IPO Event Contracts
    May 19, 2026, 1:43 PM EDT. Prediction market platform Polymarket has partnered with Nasdaq Private Market to enhance settlement of event contracts related to privately held companies, including IPO timing and valuation milestones. Nasdaq Private Market, a key provider of private market liquidity and investment infrastructure, will act as the resolution data source for these contracts. The collaboration launches new private company prediction markets on Polymarket, expanding beyond previous models relying solely on public information. This move targets a massive private market with nearly 1,600 unicorns valued at over $5 trillion, aiming to broaden access beyond institutional and high-net-worth investors. The partnership introduces more transparent and verifiable private company event markets prior to IPOs, democratizing private market engagement.

Latest articles

Top U.S. Stocks to Buy Today: 4 Names Wall Street Still Likes as Yields Bite

Top U.S. Stocks to Buy Today: 4 Names Wall Street Still Likes as Yields Bite

19 May 2026
U.S. stocks fell Tuesday as the 10-year Treasury yield reached its highest point since January 2025, pressuring growth shares. Nvidia drew the most attention ahead of its earnings, with options markets pricing in a possible $355 billion swing in value. Dell highlighted new AI infrastructure partnerships, while ServiceNow received a fresh Buy rating from Bank of America.
Nvidia’s Earnings Could Make or Break the AI Stock Trade

Nvidia’s Earnings Could Make or Break the AI Stock Trade

19 May 2026
Nvidia rose 0.8% ahead of its earnings report, while CoreWeave dropped 3.7% after Google and Blackstone announced a $5 billion U.S. AI cloud venture using Google’s custom TPUs. The new venture will offer 500 megawatts of data-center capacity by 2027. AMD and Micron also gained, but Microsoft and Broadcom slipped. Investors are watching whether Nvidia can maintain dominance as competition in AI inference intensifies.
Uranium Energy Shares Fall Close to 10% as Nuclear-Fuel Plays Get Hit

Uranium Energy Shares Fall Close to 10% as Nuclear-Fuel Plays Get Hit

19 May 2026
Uranium Energy Corp. shares dropped 9.6% to $11.93 in midday New York trading Tuesday, outpacing declines in other uranium stocks and the Global X Uranium ETF. UEC reported a $13.9 million net loss on $20.2 million in sales for its latest quarter, with 45,743 pounds of uranium concentrate produced at $44.14 per pound.
Go toTop